Supported by grants from the National Institutes of Health (R01EY030501 to ASH, U01EY033001 to HFZ, F30EY034033 to RF), by a Research to Prevent Blindness Career Advancement Award CAA (AH), by an unrestricted grant from Research to Prevent Blindness, and by a Roche/ARVO Collaborative Research Fellowship Award (SG). The sponsors or funding organizations had no role in the design or conduct of this research.
Disclosure: S. Gupta, None; X. Zhang, None; A. Panigrahi, None; Shakha, None; R. Fang, None; C.A. Strohmaier, AbbVie (R), Elios Vision (C, R), Santen Pharmaceutical (C, F), Zeiss (R); H.F. Zhang, Opticent Health (F), R.N. Weinreb, Alcon (C), Allergan (C), Amydis (C, F), Editas (C), Equinox Ophthalmic (C), Iantrek (C), iSTAR Medical (C), Santen (C), Topcon (C); V. Gupta, None; A.S. Huang, Allergan (C), Amydis (C), Celanese (C), Diagnosys (F), Equinox Ophthalmic (C), Glaukos (C, F), Heidelberg Engineering (F), QLARIS (C), Santen (C), Topcon (C)